Detalles de la búsqueda
1.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37591293
2.
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Leuk Lymphoma
; 58(7): 1598-1606, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27830957
3.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Leuk Lymphoma
; 58(5): 1084-1093, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27731748
4.
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 57(9): 2037-46, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26784000
Resultados
1 -
4
de 4
1
Próxima >
>>